Wang, TFeldman, GMHerlyn, MKaufman, RE2023-02-012023-02-0120152162-402X2162-402Xhttps://hdl.handle.net/10161/26514We have recently discovered that BRAF inhibitors induce potent macrophage responses that confer melanoma resistance to therapy. Our studies lay a foundation for the hypothesis that macrophages switch their role from a passenger to a driver for tumor survival during therapeutic treatment, suggesting that agents that target macrophages can be an important component of "cocktail" anticancer therapy.BRAF inhibitormacrophagemelanomatargeted therapyJournal article2023-02-01